Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
Year: 2025
Type: other
Abstract: Best change in tumor size from baseline for (A) IPH5201 monotherapy (n = 38) and (B) IPH5201 + durvalumab (n = 19). Patients who developed new lesion as defined per RECIST v1.1 are denoted by an asterisk (*). Data are shown based on the as-treated population, defined as all patients who received any investigational product. ad, adenocarcinoma; CRC, colorectal cancer; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; SCC, squamous cell carcinoma; sq, squamous.
Authors: John Powderly, Martina Imbimbo, Antoine Italiano, Patricia Martin-Romano, Meredith McKean, Teresa Macarulla, Eduardo Castañón Alvarez, Benedito A. Carneiro, Raymond Mager, Vicky Barnhart, Steven Eck, Elina Murtomaki, Arsène-Bienvenu Loembé, Yun He, Zachary A. Cooper, Eric Tu, Chunling Fan, Agnes Boyer Chamard, Carine Paturel, Paula G. Fraenkel, Antoine Hollebecque
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4414394280
Cites:
Cited by:
Related to: